Viatris Inc. (VTRS) is a renowned global healthcare company that was formed in 2020 following the historic merger of Upjohn, a division of Pfizer, and Mylan, a global generic and specialty pharmaceutical company. The company trades under the ticker symbol VTRS on NASDAQ.
Viatris is committed to providing people worldwide with access to high-quality medicine and creating solutions that help them enjoy healthier lives. Witharound 1.3 billion people worldwide benefiting from their products, Viatris has established a presence in approximately 165 countries and territories, and its expansive portfolio contains more than 1,400 approved molecules across a wide range of therapeutic areas.
The company has notable strengths in various therapeutic areas, including respiratory, cardiovascular diseases, oncology, infectious diseases, and diabetes. By providing top-notch healthcare services to customers, Viatris has emerged as a trusted global partner.
Viatris operates around the world with its combination of over 45,000 employees working together to empower people everywhere to live healthier at every stage of life. The company believes in empowering people worldwide to live healthier at every stage of life, and so, they imbibe this mission in all of their offerings - from treatments for widespread conditions to specialized medicines and therapies for complex diseases.
The company's approach to healthcare goes beyond conventional boundaries. They not only manufacture high-quality medicines, but also offer services and support to advance health and wellness in communities around the world. They work closely with healthcare providers, governments, and other stakeholders to ensure the right medicines and healthcare solutions reach the people who need them most.
Viatris Inc. is also known for their commitment to social responsibility. They are determined to make a positive impact on global public health and are actively involved in numerous charitable initiatives worldwide. For instance, the company's anti-retroviral (ARV) products play a significant role in helping to manage and treat HIV/AIDS in third-world countries.
In terms of financial performance, the company boasts strong revenues thanks to its diversified product portfolio and global reach. Despite being a young company, Viatris has an impressive position in the market, balanced portfolio, robust R&D capabilities, and operational excellence.
In short, Viatris aims to revolutionize healthcare by making quality health services more accessible. An undoubted pioneer, it uses its global network, a diversified portfolio, and a wide range of therapeutic areas to bring better health within the reach of people worldwide. Viatris Inc. confidently strides forward with its ambitious mission to transform public health on a global scale.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Viatris Inc. (VTRS) shares fell 1.85% on Thursday, closing at $20.67. This decline occurred during a broader market downturn, with both the S&P 500 Index and Dow Jones Industrial Average also experiencing losses. The stock's drop ended a four-day winning streak for Viatris.
MediWound technically beat EPS estimates but missed revenue consensus by 53.2% and retracted its 2026 revenue outlook due to unpredictable U.S. government funding. While the company saw improvements in gross margin, NexoBrid demand, and government contracts, its near-term financial stability is compromised, and the balance sheet required fresh equity. Investors are now focused on the mid-2027 VALUE clinical trial readout and capacity expansion rather than immediate revenue figures.
Five biotech companies—BridgeBio, Vertex, Gilead, Viatris, and Praxis—have FDA target action dates between November 27 and December 27, 2026. These PDUFA dates mark when pending applications could be decided, with Vertex's povetacicept for IgA nephropathy on November 30 being a key highlight. The report also details Q3 revenues and 2026 guidance for several companies, noting positive updates for Vertex, Gilead, and Viatris, alongside flat Q3 revenues for Viatris.
On Wednesday, November 11, 23 Mid Cap US and Canada-listed stocks within the Trefis coverage universe reached 52-week highs. Mid Cap is defined as a market value between $10 billion and $40 billion, with Cboe Global Markets (CBOE) being the largest at $38.6 billion. The Financials sector accounted for 8 of these 23 companies, while the S&P 500 was down 2.3% over the past month.
Ingram Micro (INGM) is scheduled to replace Pacira BioSciences (PCRX) in the S&P SmallCap 600 before market open on November 17. This change follows Viatris' (VTRS) anticipated acquisition of Pacira. INGM shares saw approximately a 4% increase in extended trading after the announcement.